Thrombosis and Haemostasis,
Journal Year:
2025,
Volume and Issue:
unknown
Published: May 20, 2025
Abstract
Patient
care
pathways
provide
an
integrated
approach
to
atrial
fibrillation
(AF)
management.
International
guidelines
propose
various
patient
pathways,
each
emphasizing
different
strategies
for
assessing
stroke
and
bleeding
risk.
Due
ethnicities
susceptibility
or
risk,
caution
should
be
taken
during
application
of
Western
cohorts-derived
Asian
cohorts.
Evidence-based
rather
than
eminence-based
adopted
AF
care.
In
this
clinical
focus,
we
summarize
compare
using
evidence
on
the
implementation
in
real-world
registries,
risk
across
non-Asian
guidelines.
Thrombosis and Haemostasis,
Journal Year:
2024,
Volume and Issue:
124(10), P. 897 - 911
Published: May 14, 2024
The
consensus
guidelines
of
the
Geriatric
Society
Chinese
Medical
Association
on
management
atrial
fibrillation
(AF)
in
elderly
was
first
published
2011
and
updated
2016,
with
endorsement
by
Health
Medicine.
Since
then,
many
important
studies
regarding
screening
treatment
population
have
been
reported,
necessitating
this
expert
guideline.
writing
committee
members
comprehensively
reviewed
evidence
pertaining
to
patients
AF,
formulated
2024
update.
highlighted
issues
focused
following:
for
geriatric
comprehensive
assessment,
use
Atrial
Better
Care
(ABC)
pathway
patients,
special
clinical
settings
related
AF.
New
recommendations
addressing
smart
technology
facilitated
AF
screening,
ABC
based
management,
optimal
anticoagulation
were
developed,
a
focus
elderly.
Thrombosis and Haemostasis,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 20, 2025
Atrial
fibrillation
(AF)
is
the
most
common
arrhythmia
worldwide,
contributing
significantly
to
morbidity,
healthcare
costs,
and
resource
utilization.[1]
Patients
with
AF
face
a
higher
mortality
morbidity
from
stroke,
heart
failure,
dementia,
hospitalizations.[1]
Oral
anticoagulants
(OACs)
are
cornerstone
of
management,
as
they
substantially
reduce
risk
stroke
mortality.[2]
Nevertheless,
some
residual
still
remains
despite
anticoagulation,
AF-related
linked
cardiovascular
causes
comorbidities
rather
than
alone.[2]
[3]
Thrombosis and Haemostasis,
Journal Year:
2024,
Volume and Issue:
124(12), P. 1087 - 1094
Published: Oct. 7, 2024
Abstract
Atrial
fibrillation
(AF)
is
a
complex
disease
requiring
multidomain
and
(usually)
long-term
management,
thus
posing
significant
burden
to
patients
with
AF,
practitioners,
health
care
system.
Unlike
cardiovascular
conditions
narrow
referral
pathway
(e.g.,
acute
coronary
syndrome),
AF
may
be
first
detected
by
wide
range
of
specialties
(often
noncardiology)
or
general
practitioner.
Since
timely
initiated
optimal
management
essential
for
the
prevention
AF-related
complications,
concise
simple
guidance
practitioners
managing
patients,
regardless
their
specialty.
Guideline-adherent
has
been
shown
translate
improved
patient
outcomes
compared
guideline-nonadherent
treatment.
To
facilitate
guideline
implementation
in
routine
clinical
practice,
good
document
on
should
introduce
only
evidence-based
new
recommendations,
while
avoiding
arbitrary
changes,
which
confusing
practitioners.
Herein,
we
discuss
main
changes
2024
European
Society
Cardiology
(ESC)
Guidelines
relative
previous
2020
ESC
document.
Whether
updates
recommendations
issued
guidelines
will
high
adherence
practice
(and
hence
prognosis
AF)
need
addressed
upcoming
years.
Nature Communications,
Journal Year:
2024,
Volume and Issue:
15(1)
Published: Aug. 7, 2024
Female
sex
has
been
suggested
as
a
risk
modifier
for
stroke
in
patients
with
atrial
fibrillation
(AF)
comorbid
prevalent
factors.
Management
evolved
over
time
towards
holistic
approach
that
may
have
diminished
any
difference
AF-related
stroke.
In
nationwide
cohort
of
AF
free
from
oral
anticoagulant
treatment,
we
examine
the
trends
overall
and
relation
to
differences
between
male
female
patients.
Here
show
among
158,982
(median
age
78
years
(IQR:
71
85);
52%
female)
1-year
thromboembolic
was
highest
1997-2000
5.6%
lowest
2013-2016
3.8%,
declining
last
two
decades.
The
excess
vs
also
declining,
risk-score
adjusted
relative
estimates
suggesting
limited
sex-difference
recent
years.
EP Europace,
Journal Year:
2024,
Volume and Issue:
26(11)
Published: Nov. 1, 2024
Abstract
Aims
The
CHA2DS2VASc
score
is
recommended
for
stroke
risk
stratification
in
patients
with
atrial
fibrillation
(AF).
This
assigns
one
extra
point
to
female
sex
based
on
evidence
from
the
early
2000s,
suggesting
higher
thromboembolic
women.
incremental
of
thromboembolism
women
has
decreased
over
time
between
2007
and
2018,
becoming
non-significant
recent
years.
objective
this
study
was
assess
impact
removing
category
(Sc)
score,
thus
validating
a
non-sex
(i.e.
CHA2DS2VA)
score.
Methods
results
We
analysed
UK
primary
secondary
care
data
comprising
195
719
AF
followed
1998
2016
(mean
age:
75.9
±
12.3
years;
49.2%
women).
Among
126
428
non-anticoagulated
patients,
we
compared
vs.
CHA2DS2VA
scores
every
calendar
year.
Throughout
413
007
patient-years,
total
8742
events
ischaemic
or
systemic
embolism
were
recorded.
Sex
differences
not
observed
lower-risk
population,
but
rates
consistently
seen
higher-risk
≥2).
C-statistics
both
similar
years
(ranging
0.62
0.71).
With
CHA2DS2VA,
no
relevant
integrated
discrimination
improvement,
net
reclassification
improvement
(NRI)
resulted
improved
(11%)
lower
groups.
NRI
suggested
misclassification
(−7%),
did
affect
their
indication
anticoagulation
retained
high-risk
status).
Conclusion
Removing
Sc
does
its
ability
discriminate
population
AF.
use
may
simplify
initial
decision-making
thromboprophylaxis.
Thrombosis and Haemostasis,
Journal Year:
2025,
Volume and Issue:
125(01), P. 001 - 002
Published: Jan. 1, 2025
As
we
begin
2025,
it
is
a
time
to
reflect
on
our
journey
and
the
exciting
initiatives
that
continue
shape
future
of
Thrombosis
&
Haemostasis.
This
editorial
offers
moment
celebrate
recent
achievements
introduce
new
strategies,
collaborations,
opportunities
look
forward
in
year
ahead.
Thrombosis and Haemostasis,
Journal Year:
2025,
Volume and Issue:
125(01), P. 085 - 091
Published: Jan. 1, 2025
This
year's
Editors'
Choice
highlights
some
of
the
most
impactful
2024
publications
in
Thrombosis
and
Haemostasis
(TH)
its
open-access
companion
journal
TH
Open.The
selection
reflects
key
trends
field,
including
new
guidelines,
emerging
therapies,
diagnostic
technologies
reshaping
treatment
approaches
as
well
practical
challenges
related
to
implementation,
adherence,
patient
outcomes.Additionally,
role
genetics,
lifestyle,
recently
emerged
conditions
such
COVID-19
thrombosis
came
forefront
research
published
last
year.
